Drug Trial Radar · NCT06545162
Safety, Tolerability, and Pharmacokinetics of a Single or Multiple Ascending Doses of CPX101
Last checked: Nov 19, 2026Latest source record: Apr 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
72
Actual
Start
Dec 4, 2024
Primary completion
Dec 30, 2025
Study completion Dec 30, 2025
Sponsor
- Lead sponsor
- Guangzhou Chia Tai Innovative Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 9, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This randomized, double-blind, placebo-controlled Phase I clinical study was designed to evaluate the tolerability and safety, PK profile, immunogenicity of CPX101 in a single dose in healthy participants and multiple doses in overweight and obese patients, and to initially explore the efficacy of multiple doses in weight loss. The study was divided into two parts: single administration and dose escalation (SAD) and multiple administration and dose escalation (MAD).
Conditions
- Overweight and Obesity
Interventions
CPX101 or placebo 80mg single doseBiological
Subcutaneous injection of CPX101 or placebo
CPX101 or placebo 120mg single doseBiological
Subcutaneous injection of CPX101 or placebo
CPX101 or placebo 160mg single doseBiological
Subcutaneous injection of CPX101 or placebo
CPX101 or placebo 80mg Q2WBiological
Subcutaneous injection of CPX101 or placebo
CPX101 or placebo 120mg Q2WBiological
Subcutaneous injection of CPX101 or placebo
CPX101 or placebo 160mg Q2WBiological
Subcutaneous injection of CPX101 or placebo
CPX101 or placebo 320mg Q2WBiological
Subcutaneous injection of CPX101 or placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- The safety of CPX101Time frame: Up to 84 days after administration
- The tolerability of CPX101Time frame: Up to 84 days after administration
- The safety of CPX101Time frame: Up to 196 days after administration
- The tolerability of CPX101Time frame: Up to 196 days after administration
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Beijing Friendship Hospital
Beijing, Beijing Municipality, China
Beijing hospital
Beijing, Beijing Municipality, China
Beijing Luhe hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.